Epilepsy Trial, Recruiting NCT05992402 Sponsor: Kayela Arrotta Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT05992402
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 60 years old who have been diagnosed with epilepsy and whose epilepsy specialist has confirmed them as a suitable candidate for surgery
  • People who are able to give their own consent to participate without assistance
  • People who are fluent in English
  • People whose reading level is at or above an 8th grade standard, as measured by a specific reading test (the WRAT-4)
  • People who have access to the internet and are able to participate in online video streaming
  • People who have not previously had brain surgery to remove or destroy brain tissue, though prior use of nerve stimulation devices (such as RNS, VNS, or DBS) is acceptable
  • People who are willing and able to take part in a program aimed at improving thinking and memory skills

Who may not be able to join:

  • People who have taken part in any kind of cognitive (thinking or memory) rehabilitation or training program within the last 6 months
  • People who are involved in an ongoing legal case related to the cause of their epilepsy, unless that legal matter is only about a disability application (short- or long-term)
  • People currently undergoing intensive treatment for a serious or life-threatening illness, such as chemotherapy, that could affect their ability to participate
  • People with a serious psychiatric condition that could interfere with participation, such as schizophrenia, active psychosis, active mania, or current thoughts of suicide
  • People with significant hearing or vision loss that would prevent participation in remote cognitive testing or the cognitive training program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kayela Arrotta, PhD, The Cleveland Clinic

Phone: 216-444-6101

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Kayela Arrotta
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Intervention attendance; Rate of Homework Completion; Study Attrition; Intervention Efficacy based on Quality of Life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov